Literature DB >> 2945728

Impaired humoral immune response in complement C3-deficient guinea pigs: absence of secondary antibody response.

E C Böttger, S Metzger, D Bitter-Suermann, G Stevenson, S Kleindienst, R Burger.   

Abstract

A recently described genetically controlled C3 deficiency (C3D) in guinea pigs (GP) provided a unique model for studying the role of C3 in the afferent limb of the humoral immune response in a direct manner. These C3D animals, which have only 5-7% of normal serum C3 level, were immunized with the bacteriophage phi chi 174, a T cell-dependent antigen, followed by a booster injection after 4 weeks (1.5 X 10(9) plaque-forming units/kg). The formation of IgM and IgG antibody in the course of the primary and secondary response was determined and compared with a control group of inbred strain 2 GP. The C3D animals showed a markedly diminished antibody response to this antigen. Amplification of the antibody titer as well as regular isotype switching from IgM to IgG was absent in the secondary response. Increasing the amount of antigen to a high dose (1 X 10(10) plaque-forming units/kg) led to a normalization of the antibody response. The impairment in antibody formation resembles closely the impaired antibody response in C4-deficient or C2-deficient GP, which both have a block in activation of C3 via the classical pathway. However, in contrast to C4D GP or C2D GP the C3D GP do not exhibit serological characteristics of immune complex disease. They have normal levels of total serum IgM, of IgM anti-2,4-dinitrophenyl antibodies and of IgM rheumatoid factors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2945728     DOI: 10.1002/eji.1830161008

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  20 in total

Review 1.  The role of complement in the acquired immune response.

Authors:  C H Nielsen; E M Fischer; R G Leslie
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

Review 2.  Complement deficiency.

Authors:  K M O'Neil
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

Review 3.  Evolution of complement as an effector system in innate and adaptive immunity.

Authors:  J Oriol Sunyer; Hani Boshra; Gema Lorenzo; David Parra; Bruce Freedman; Nina Bosch
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

4.  Development of antibodies against tetravalent meningococcal polysaccharides in revaccinated complement-deficient patients.

Authors:  M Drogari-Apiranthitou; C A Fijen; D Van De Beek; E F Hensen; J Dankert; E J Kuijper
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

5.  Covalent binding of C3b to tetanus toxin: influence on uptake/internalization of antigen by antigen-specific and non-specific B cells.

Authors:  M B Villiers; C L Villiers; M R Jacquier-Sarlin; F M Gabert; A M Journet; M G Colomb
Journal:  Immunology       Date:  1996-11       Impact factor: 7.397

6.  Antigen-bound C3b and C4b enhance antigen-presenting cell function in activation of human T-cell clones.

Authors:  J Arvieux; H Yssel; M G Colomb
Journal:  Immunology       Date:  1988-10       Impact factor: 7.397

7.  Humoral response to herpes simplex virus is complement-dependent.

Authors:  X J Da Costa; M A Brockman; E Alicot; M Ma; M B Fischer; X Zhou; D M Knipe; M C Carroll
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

Review 8.  Complement and humoral immunity.

Authors:  Michael C Carroll
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

9.  Complement activation in human lymphoid germinal centres.

Authors:  J Zwirner; E Felber; P Schmidt; G Riethmüller; H E Feucht
Journal:  Immunology       Date:  1989-02       Impact factor: 7.397

10.  C3- and T-cell-dependent adjuvant activity of in vivo formed immune complexes.

Authors:  C W Van den Berg; M A Hazenberg; F M Hofhuis; S M Van Rooyen; H Van Dijk
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.